Archie Goodburn, a 24-year-old British swimmer and rising star in the sport, is using his platform to advocate for more significant government investment in brain cancer research. Diagnosed with a rare, inoperable form of the disease, Goodburn’s experiences have prompted him to call for urgent changes in how brain tumours are treated and funded in the UK.
A Life-Altering Diagnosis
Goodburn’s journey took a dramatic turn two years ago when he began experiencing alarming symptoms during training sessions. Initially, he encountered episodes of weakness, numbness on his left side, and an overwhelming sense of fear and nausea. “I felt like my consciousness was being pulled away from me,” he recalls. Tragically, just before the Paris Olympics qualifiers in April 2024, Goodburn learned that he had three oligodendrogliomas—tumours that account for a mere 3% of all brain cancer cases.
Despite the bleak prognosis, Goodburn found a lifeline in Vorasidenib, a breakthrough medication that allowed him to return to competition just in time for the upcoming Commonwealth Games in Glasgow. This drug has temporarily postponed the need for chemotherapy and radiotherapy, treatments that could severely hinder both his athletic career and his studies in chemical engineering.
A Call for More Progress
Despite his positive response to Vorasidenib, Goodburn is acutely aware that one new drug in two decades is insufficient. He insists, “Vorasidenib only bought me four years, according to the trials. I need more. And I’m not going to stop [campaigning] until my last breath.” This sentiment reflects a broader frustration within the brain cancer community, as the disease remains the leading cancer killer among children and adults under 40. Alarmingly, since 2002, brain cancer research has received only 1% of the UK government’s national cancer research budget.
Goodburn highlights a troubling “translational gap” in research funding, where promising early-phase studies often fail to reach clinical trials due to a lack of financial support. This disconnect, dubbed the “valley of death” by the all-party parliamentary group on brain tumours, stems from a risk-averse funding system that hampers breakthroughs in treatment.
Advocacy for Change
Goodburn, alongside the Brain Cancer Justice campaign, is calling on the government to expedite the release of the £40 million pledged for brain cancer research in 2018, ensuring that it is directed to frontline scientists. They are also advocating for the appointment of a dedicated brain cancer lead within the government, greater access to genome sequencing for newly diagnosed patients, and the establishment of a “right to try” policy for experimental treatments.
In response to the growing advocacy, the Department of Health and Social Care has acknowledged the need for enhanced research into brain tumours and is committed to improving patient access to innovative treatments. However, Goodburn remains sceptical, having witnessed the slow pace of change firsthand.
A Personal Journey and a Broader Mission
As he prepares for the Commonwealth Games, where he aims to compete in the 50m breaststroke, Goodburn finds himself balancing the demands of training with his advocacy efforts in Westminster. The upcoming debate on his petition in the House of Commons marks a critical moment for him and others affected by brain cancer. “I campaign, if I’m being completely honest, because of the disparity in care, the lack of funding, but also because I believe that my campaigning can actually make a difference to my own future,” he stated. “In some ways, it’s a treatment of its own.”
Goodburn’s tenacity highlights the urgent need for systemic changes in how brain cancer is addressed in the UK. His journey serves not only as a personal testament to resilience but as a rallying cry for change that could benefit countless others facing similar battles.
Why it Matters
Archie Goodburn’s story underscores the critical need for increased funding and support for brain cancer research in the UK. With the disease being one of the most lethal forms of cancer, particularly among younger populations, the lack of investment in innovative treatments is unacceptable. Goodburn’s advocacy not only aims to improve his own prospects but also seeks to ignite a broader conversation about the urgent need for reform in cancer care, reminding us that every voice matters in the fight for health equity.
